Eli Lilly's next-generation GLP-1 drug, Retatrutide, shows promising early trial results with some patients losing 30% or more of their body weight, comparable to bariatric surgery outcomes. However, the drug remains in development and results vary among patients. Meanwhile, Lilly's new GLP-1 pill appears less effective than competitor Novo Nordisk's offering, potentially facing market acceptance challenges.

The article recommends three undervalued growth stocks for investors with $2,000 to deploy: Shopify, which has declined 40% but remains the future of e-commerce; Nice Ltd, a customer service automation specialist with strong AI integration potential; and Viking Therapeutics, an emerging weight-loss drug developer with a potentially superior GLP-1 alternative in phase 3 trials.

While Eli Lilly leads the GLP-1 weight loss drug market with strong sales growth, Novo Nordisk's new pill version of Wegovy is attracting new customers and offers better value. Eli Lilly's stock is richly valued at 37x P/E with a 0.65% dividend yield, whereas Novo Nordisk trades at 10x P/E with a 4% yield, making it more attractive for dividend and value investors despite near-term pricing pressures.

President Trump's Q1 2026 financial disclosures revealed significant purchases of Eli Lilly stock, a major player in the booming anti-obesity drug market. The article cautions investors against simply copying political trades, emphasizing that investment decisions should be based on business fundamentals rather than celebrity or political endorsements. Eli Lilly's obesity treatments Mounjaro and Zepbound generated over $30 billion in combined sales in 2025, with analysts projecting the global anti-obesity drug market could exceed $95-200 billion. While Lilly maintains a strong competitive position with manufacturing advantages and a robust pipeline, its premium valuation already reflects years of future growth, presenting significant downside risk if sales slow or competition intensifies.

The obesity drug market is projected to reach nearly $100 billion by decade's end. While Eli Lilly and Novo Nordisk dominate, two other companies—Viking Therapeutics and AbbVie—are positioned for significant growth. Viking is advancing VK-2735, a dual GLP-1/GIP receptor agonist in phase 3 trials with promising results. AbbVie is developing ABBV-295, a long-acting amylin analog with positive phase 1 data. Both stocks are predicted to potentially double in 2026 based on upcoming trial results and market expansion.

The global bioprocess automation software market is projected to grow from USD 1.67 billion in 2025 to USD 6.19 billion by 2035, at a 14% CAGR. Growth is driven by the shift toward personalized medicine, modular manufacturing approaches, and increased adoption of automation in biopharmaceutical production. Pharmaceutical and biotech manufacturers are expected to dominate the market segment.

Morgan Stanley highlighted Eli Lilly's strong international GLP-1 performance, particularly in India where Mounjaro grew 10% despite generic competition from Novo Nordisk's Wegovy. Eli Lilly controls over 50% of the international GLP-1 market, driven by superior weight-loss efficacy. While the company faces valuation concerns at 38x P/E, Morgan Stanley suggests the market may be underestimating its international growth potential.

Eli Lilly achieved a significant phase 3 trial win with retatrutide, a weight loss drug candidate that demonstrated superior efficacy compared to current market leaders. The drug helped patients lose an average of 28% of body weight over 80 weeks by acting on three hormonal pathways, compared to Novo Nordisk's single-pathway and Lilly's existing dual-pathway drugs. With 60% U.S. market share and this promising new candidate, Lilly is positioned to maintain dominance in the rapidly growing weight loss drug market expected to reach $100 billion by the early 2030s.

Viking Therapeutics is increasingly viewed as an acquisition target for large pharmaceutical companies seeking obesity drug exposure. The company's lead candidate VK2735 shows strong efficacy data in both injectable and oral formulations, with Phase 3 trials underway. With a market cap of $3.6B and $603M in cash, Viking trades at $30/share while analysts project $95 price targets, making it potentially cheaper for big pharma to acquire than develop competing assets independently.

Pfizer's stock has declined over 50% from its 2021 peak as Wall Street focuses on competitors' GLP-1 weight-loss drugs. Despite current challenges including failed GLP-1 development and upcoming patent expirations, the article argues Pfizer remains a well-run pharmaceutical giant with a strong pipeline in oncology, vaccines, and migraine drugs. With a 6.7% dividend yield and a history of successful pivots, Pfizer could be an attractive long-term turnaround opportunity for patient investors.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Wegovy® 7.2 mg in a single-dose pen for obesity treatment in the EU, with expected launch in Q3 2026. The STEP UP trial demonstrated 20.7% mean weight loss, with approximately one-third of patients achieving 25% or greater weight loss. Additionally, CHMP recommended approval of Wegovy® oral semaglutide pill as the first oral GLP-1 obesity treatment in its class.

Eli Lilly's oral GLP-1 medication Foundayo showed strong results in weight-loss maintenance trials, supporting the company's two-pronged strategy to capture market share. The ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable Zepbound to oral Foundayo retained 80% of their weight loss after 52 weeks, significantly outperforming those who discontinued GLP-1s entirely. While Foundayo lags behind Novo Nordisk's Wegovy pill in initial weight loss efficacy, Lilly's advantage in maintenance therapy and lack of dietary restrictions positions it competitively. Lilly shares rose 2.4% on the data release, with Wall Street analysts maintaining a consensus price target of $1,218, implying over 20% upside.